BCV
VKTX icon

Banque Cantonale Vaudoise’s Viking Therapeutics VKTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126K Hold
3,881
– – ﹤0.01% 693
2025
Q4 		$136K Buy
3,881
+129
+3% +$4.57K ﹤0.01% 598
2025
Q3 		$98K Buy
3,752
+536
+17% +$16K ﹤0.01% 621
2025
Q2 		$85K Hold
3,216
– – ﹤0.01% 607
2025
Q1 		$77K Buy
+3,216
New +$102K ﹤0.01% 654

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Banque Cantonale Vaudoise's VKTX Position: Q1 2026 in Review

Banque Cantonale Vaudoise held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 3,881 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Banque Cantonale Vaudoise first reported a position in VKTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $136K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Banque Cantonale Vaudoise held 3,881 shares of Viking Therapeutics worth $126K as of Q1 2026.
  • Banque Cantonale Vaudoise left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #693 holding.
  • Banque Cantonale Vaudoise first reported a position in Viking Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Banque Cantonale Vaudoise's Viking Therapeutics position peaked at $136K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.